Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TQB 2868

Drug Profile

TQB 2868

Alternative Names: TQB-2868

Latest Information Update: 11 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chia Tai Tianqing Pharmaceutical Group
  • Class Antineoplastics; Immunotherapies; Recombinant fusion proteins
  • Mechanism of Action Programmed cell death-1 ligand-1 inhibitors; Transforming growth factor beta replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Cancer

Most Recent Events

  • 01 Jun 2024 Fundan University plans a phase II trial in Liver cancer (Late-stage disease, Combination therapy, Second line therapy or greater) in China (parentral, Injection) (NCT06441019)
  • 20 Nov 2023 Chia Tai Tianqing Pharmaceutical Group withdraw a phase-II trial for Cervical cancer (Metastatic disease, Combination therapy, First-line therapy,) in China (IV) due to slow progress in development, the sponsor decided to withdraw and no longer proceed (NCT05998941)
  • 23 Aug 2023 Chia Tai Tianqing Pharmaceutical Group plans a phase-II trial for Cervical cancer (Metastatic disease, Combination therapy, First-line therapy,) in China (IV) (NCT05998941)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top